Xpovio 20 mg Tablet

Description

Xpovio 20 mg Tablet contains selinexor, a targeted anticancer medicine classified as a selective inhibitor of nuclear export (SINE). It is used in the treatment of certain blood cancers, particularly multiple myeloma, and in some cases diffuse large B-cell lymphoma (DLBCL). Selinexor works by blocking a protein called exportin-1 (XPO1), which plays a role in transporting tumor suppressor proteins out of the cell nucleus. In many cancer cells, overactivity of exportin-1 can lead to reduced activity of tumor-suppressing proteins that help control abnormal cell growth. By inhibiting this transport mechanism, selinexor helps restore the activity of these proteins and may slow or stop cancer cell proliferation when used as prescribed by a qualified healthcare professional. Xpovio tablets are taken orally and are usually prescribed as part of combination therapy with other anticancer medicines

Benefits

• Targets exportin-1 (XPO1), a protein involved in cancer cell survival

• Represents a novel mechanism of action in cancer treatment

• Oral tablet therapy that can be taken outside hospital settings

• Often used in combination regimens for relapsed or refractory cancers

• Part of modern targeted therapy approaches in hematologic oncology

Indications and Usage

Xpovio (selinexor) may be prescribed for:

• Multiple myeloma, often in combination with other anticancer medicines

• Relapsed or refractory multiple myeloma in patients who have received prior therapies

• Diffuse large B-cell lymphoma (DLBCL) in certain treatment situations

Treatment decisions depend on disease type, prior treatments, and clinical evaluation.

How it Works

Selinexor works by inhibiting exportin-1 (XPO1), a nuclear export protein responsible for transporting certain regulatory proteins from the nucleus to the cytoplasm of the cell. In many cancer cells, XPO1 is overexpressed, which leads to the removal of tumor suppressor proteins from the nucleus, weakening their ability to control cell growth.

By blocking XPO1, selinexor helps retain tumor suppressor proteins within the cell nucleus, restoring their function in regulating cell division and promoting cancer cell death. This mechanism may help slow disease progression when the medicine is used as prescribed and monitored by an oncology specialist.

Dosage & Administration

• Xpovio tablets are taken orally with water.

• The medicine is usually taken once or twice weekly, depending on the treatment regimen prescribed by the healthcare professional.

• Tablets should be swallowed whole and not crushed or chewed.

• The medicine may be taken with or without food, unless directed otherwise.

• Dose adjustments may be required depending on treatment tolerance and laboratory findings.

Side Effects

Common side effects

• Nausea

• Fatigue

• Loss of appetite

• Diarrhea

• Low blood platelet counts (thrombocytopenia)

• Weight loss

Serious side effects

• Severe low blood cell counts

• Serious infections

• Severe nausea or vomiting

• Hyponatremia (low sodium levels)

• Neurological symptoms such as confusion or dizziness

Patients should seek medical attention if severe symptoms occur.

Warning and Precaution

• Risk of severe thrombocytopenia (low platelet count)

• Possible serious infections due to immune suppression

• Risk of low sodium levels (hyponatremia)

• Severe nausea, vomiting, or weight loss may occur

• Monitor blood counts and electrolyte levels during treatment

• Inform healthcare providers about all medications and supplements being used

• Pregnancy should be avoided during therapy

Patient Guidance

• Take the medicine exactly as prescribed by your oncologist

• Attend scheduled blood tests and monitoring appointments

• Report symptoms such as unusual bleeding, severe fatigue, or infections

• Follow guidance on hydration and nutrition during treatment

• Inform your doctor about all medications and supplements

• Do not stop treatment without consulting your healthcare provider

Clinical Trial & Approvals

Selinexor has been studied in clinical trials evaluating treatment for relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma. Trials such as the STORM and BOSTON studies demonstrated clinical activity of selinexor-based regimens in certain patient populations. Based on these results, selinexor received approvals from regulatory authorities including the U.S. Food and Drug Administration (FDA) for specific oncology indications.

References

• U.S. Food and Drug Administration (FDA) – Selinexor Prescribing Information
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212306s011lbl.pdf

• European Medicines Agency (EMA) – Selinexor Product Information
  https://www.ema.europa.eu

• National Cancer Institute – Selinexor Drug Information
  https://www.cancer.gov

• Drugs.com – Selinexor Drug Information
  https://www.drugs.com

• ClinicalTrials.gov – Selinexor Clinical Studies
  https://clinicaltrials.gov

Prescription & documentation note

Xpovio 20 mg Tablet is typically supplied against a valid prescription. For international orders, patients may need to provide documentation such as a licensed physician’s prescription, identification, and country-specific import documentation, depending on destination regulations. MedsMonk may assist with documentation guidance where applicable.